Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | GCK | P35557 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | ABL1 | P00519 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1981547 | 0.82 | ALDH1A1 (0.42) | SMN1; SMN2MAPTALDH1A1HTTKMT2A | |
| SCHEMBL30764819 | 0.82 | MAPT (0.43) | SMN1; SMN2MAPTALDH1A1HTTKMT2A | |
| SCHEMBL21617088 | 0.82 | MAPT (0.43) | SMN1; SMN2MAPTALDH1A1HTTKMT2A | |
| SCHEMBL2657748 | 0.80 | MAPT (0.43) | HCAR3SMN1; SMN2MAPTALDH1A1HTT | |
| SCHEMBL30199709 | 0.78 | ALDH1A1 (0.53) | SMN1; SMN2MAPTALDH1A1HTTKMT2A | |
| SCHEMBL228082 | 0.78 | ALDH1A1 (0.53) | SMN1; SMN2MAPTALDH1A1HTTKMT2A | |
| SCHEMBL1981549 | 0.78 | MAPT (0.51) | SMN1; SMN2MAPTALDH1A1HTTKMT2A | |
| SCHEMBL2986961 | 0.77 | MAPT (0.48) | SMN1; SMN2MAPTALDH1A1HTTKMT2A | |
| SCHEMBL3542592 | 0.74 | CYP2D6 (0.53) | ALDH1A1KMT2AMEN1GCKLMNA | |
| SCHEMBL3543501 | 0.74 | CYP2D6 (0.53) | ALDH1A1KMT2AMEN1GCKLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1966152-A2 | GLUCOKINASE ACTIVATORS | Takeda Pharmaceutical Company Limited (JP) | 2008-09-10 | — | — | EP | disclosed |
| US-20070244169-A1 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. | 2007-10-18 | — | — | US | disclosed |
| US-20070244169-A1 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. | 2007-10-18 | — | — | US | disclosed |
| US-20070244169-A1 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. | 2007-10-18 | — | — | US | disclosed |
| WO-2007075847-A2 | GLUCOKINASE ACTIVATORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244169-A1 | GLUCOKINASE ACTIVATORS | GCK, GCKR, GALK1 | HCAR3 1883/4885SMN1; SMN2 4119/4885MAPT 3294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.